Assessment of endpoints
Tumors, death, Tumor
TUMORS, DISEASE PROGRESSION, TUMOR
The primary endpoint of the ATX study was investigator-assessed PFS, defined as the time from randomization to disease progression or death from any cause, whichever came first. Tumor assessment was performed according to Response Evaluation Criteria in Solid Tumors (RECIST 1.0) every 3 months by computed tomography or magnetic resonance imaging. Secondary endpoints were overall survival (OS), defined as time from randomization to death from any cause, and objective response rate (ORR). ORR was defined as the percentage of complete and partial response confirmed after a minimum of four weeks after first being reported.